Michael Cookson, MD,MHA

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Progenics Phamaceuticals, Inc. (Lanthues)
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Lantheus
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Janssen Pharmaceuticals
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Nonagen Bioscience Corp.
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pacifice Edge Diagnostics
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Prokarium
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2023
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer Healthcare Pharmaceuticals
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2023
Return to Incorporating the AUA/SUO Guideline on Advanced Prostate Cancer into Practice (2023) - English